Table 1 Clinical and pathological characteristics of the patient cohort
From: CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer
| Â | Positive | Negative | Â | Â |
|---|---|---|---|---|
Estrogen-Receptor | 175 (72%) | 68 (28%) | Â | Â |
Progestrone-Receptor | 136 (56%) | 108 (44%) | Â | Â |
HER2-positive (over-expressed) | 20 (14%) | 121 (86%) | Â | Â |
Ki67-positive (>14% positivity) | 84 (60%) | 55 (40%) | Â | Â |
|  | 1986–1991 | 1991–1996 | 1996–2001 | 2001–2004 |
Year of Diagnosis | 81 (30%) | 121 (46%) | 60 (23%) | 3 (1%) |
|  | 26–42 | 42–58 | 58–74 | 74–91 |
Age at Diagnosis | 36 (14%) | 104 (39%) | 80 (30%) | 45 (17%) |
|  | 5–30 | 30–55 | 55–80 | 80–100 |
Tumour size (mm) | 94 (77%) | 24 (20%) | 1 (1%) | 3 (2%) |
Nodal status | 112 (64%) | 63 (36%) | Â | Â |
| Â | + | ++ | +++ | Â |
Histological Grade | 19 (13%) | 62 (41%) | 69 (46%) | Â |